# EDGAR Filing Document

**Accession Number:** 0001337013
**File Stem:** 0001628280-26-034217
**Filing Date:** 2026-5
**Character Count:** 12616
**Document Hash:** 48ad0a42fa2c7b9064f8e76f108fea81
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-034217.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001628280-26-034217

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260511

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InfuSystem Holdings, Inc
- **CENTRAL INDEX KEY:** 0001337013
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 203341405
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35020
- **FILM NUMBER:** 26969932

**BUSINESS ADDRESS:**
- **STREET 1:** 3851 WEST HAMLIN ROAD
- **CITY:** ROCHESTER HILLS
- **STATE:** MI
- **ZIP:** 48309
- **BUSINESS PHONE:** (248) 291-1210

**MAIL ADDRESS:**
- **STREET 1:** 3851 WEST HAMLIN ROAD
- **CITY:** ROCHESTER HILLS
- **STATE:** MI
- **ZIP:** 48309

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HAPC, Inc.
- **DATE OF NAME CHANGE:** 20060425

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Healthcare Acquisition Partners Corp.
- **DATE OF NAME CHANGE:** 20050824

?xml version='1.0' encoding='ASCII'? infu-20260511

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): May 11, 2026**

**___________________________________**

**InfuSystem Holdings, Inc.**

(Exact name of registrant as specified in its charter)

**___________________________________**

---

| | | |
|:---|:---|:---|
| **Delaware**<br>(State or other jurisdiction of <br>incorporation or organization) | **001-35020**<br>(Commission File Number) | **20-3341405**<br>(I.R.S. Employer Identification Number) |
| **3851 West Hamlin Road**<br>**Rochester Hills, Michigan 48309** | **3851 West Hamlin Road**<br>**Rochester Hills, Michigan 48309** | **3851 West Hamlin Road**<br>**Rochester Hills, Michigan 48309** |
| &nbsp;&nbsp;&nbsp;&nbsp;(Address of principal executive offices) (Zip Code) | &nbsp;&nbsp;&nbsp;&nbsp;(Address of principal executive offices) (Zip Code) | &nbsp;&nbsp;&nbsp;&nbsp;(Address of principal executive offices) (Zip Code) |
| **(248) 291-1210** | **(248) 291-1210** | **(248) 291-1210** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
|  | **Not Applicable** |  |
| (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) |

---

**___________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

**☐** Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

**☐** Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

**☐** Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

**☐** Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on which Registered** |
| **Common Stock, par value $.0001 per share** | **INFU** | **NYSE American LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

At the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") of InfuSystem Holdings, Inc. (the "Company") held on May 11, 2026, the Company's stockholders approved the Third Amendment (the "Third Amendment") to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (as amended, the "2021 Plan"), which was previously approved by the Company's Board of Directors (the "Board"). The Third Amendment increased the maximum number of shares of the Company's common stock (the "Common Stock") reserved for issuance under the 2021 Equity Plan to 7,000,000 shares. The terms of the 2021 Plan provide for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, other equity-based awards and cash awards. The 2021 Plan is administered by the Board's Compensation Committee, which committee has full power to select participants to whom awards may be granted and to determine the types of awards to be granted, the number of shares to be covered by each award granted and the terms and conditions of each award granted, among other things. Eligible participants under the 2021 Plan include employees, consultants, and directors of the Company and its affiliates.

The foregoing summary of the Third Amendment does not purport to be complete and is qualified in its entirety by reference to the Third Amendment a copy of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

**Item 5.07 - Submission of Matters to a Vote of Security Holders**

At the 2026 Annual Meeting of Stockholders of the Company held on May 11, 2026, the stockholders were asked to vote on four Company proposals. A brief description of each proposal, along with the outcome and tabulation of voting results, is set forth below:

**<u>Proposal No. 1:</u>**

*The Company's Board Nominees*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| Kenneth D. Eichenbaum, MD, MSE | 11921195 | 827929 | 321555 | 3728285 |
| Paul A. Gendron | 12614275 | 276474 | 179930 | 3728285 |
| Ronald Hundzinksi | 12368646 | 611294 | 90739 | 3728285 |
| Beverly A. Huss | 11890777 | 847243 | 332659 | 3728285 |
| Carrie Lachance | 12920694 | 65053 | 84932 | 3728285 |
| Scott Shuda | 11914592 | 834532 | 321555 | 3728285 |
| Dr. John J. Sviokla | 12227773 | 521341 | 321565 | 3728285 |

---

All seven of the Company's Board nominees (Drs Eichenbaum and Sviokla, Messrs. Gendron, Hundzkinski, and Shuda and Mses. Huss and Lachance) were elected to the Board.

**<u>Proposal No. 2:</u>**

The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 11,915,842 | 1,071,346 | 83,491 | 3,728,285 |

---

**<u>Proposal No. 3:</u>**

The Company's stockholders approved the amendment to the Company's 2021 Equity Plan to increase the number of authorized shares under the 2021 Equity Plan as follows:

------

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 10,770,778 | 2,199,707 | 100,194 | 3,728,285 |

---

**<u>Proposal No. 4:</u>**

The Company's stockholders ratified the appointment of Grant Thornton LLP as the Company's registered independent accounting firm for the fiscal year ending December 31, 2026 as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 16,604,725 | 613 | 193,626 | 0 |

---

**Item 9.01 - Financial Statements and Exhibits**

**(d) Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>Description</u>** |
| <u>[10.1](infu20260511-exx101x2021eq.htm)</u> | &nbsp;&nbsp;<u>[Third](infu20260511-exx101x2021eq.htm)[Amendment to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan, dated May 1](infu20260511-exx101x2021eq.htm)[1](infu20260511-exx101x2021eq.htm)[, 202](infu20260511-exx101x2021eq.htm)[6](infu20260511-exx101x2021eq.htm)[.](infu20260511-exx101x2021eq.htm)</u> |
| &nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| INFUSYSTEM HOLDINGS, INC. | INFUSYSTEM HOLDINGS, INC. |
| By: | /s/ Barry Steele |
|  | Barry Steele |
|  | Chief Financial Officer |

---

Dated: May 12, 2026

## Exhibit 10.1

Exhibit 10.1

**THIRD AMENDMENT**

**TO THE**

**INFUSYSTEM HOLDINGS, INC.**

**2021 EQUITY INCENTIVE PLAN**

**THIS THIRD AMENDMENT** to the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan (the "Plan") was adopted by the Board of Directors (the "Board") on April 2, 2026 and approved by the stockholders of InfuSystem Holdings, Inc. (the "Company") on May 11, 2026.

**WHEREAS,** the Company maintains the Plan to (i) attract and retain the types of employees, consultant and directors who will contribute to the Company's long range success; (ii) provide incentives that align the interests of employees, consultant and directors with those of the stockholders of the Company; and (iii) promote the success of the Company's business;

**WHEREAS,** pursuant to Section 17 of the Plan, the Board may amend the Plan subject to stockholder approval as required; and

**WHEREAS,** the Board desires to amend the Plan to increase the number of shares of the Company's common stock available for the granting of awards under Section 5 of the Plan.

**NOW, THEREFORE,** the Board hereby amends the Plan, effective upon the date of stockholder approval, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 5.1 of the Plan is hereby deleted in its entirety and replaced with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***5.1. Total Share Reserve.*** *Subject to adjustment in accordance with Section 15, no more than seven million (7,000,000) shares of Common Stock plus the number of shares of Common Stock underlying any award granted under the InfuSystem Holdings, Inc. 2014 Equity Plan that expires, terminates or is canceled or forfeited under the terms of the InfuSystem Holdings, Inc. 2014 Equity Plan shall be available for the grant of Awards under the Plan (the "<u>Total Share Reserve</u>"). Any shares of Common Stock granted in connection with Options and Stock Appreciation Rights shall be counted against this limit as one (1) share for every one (1) Option or Stock Appreciation Right awarded. Any shares of Common Stock granted in connection with Awards other than Options and Stock Appreciation Rights shall be counted against this limit as two (2) shares of Common Stock for every one (1) share of Common Stock granted in connection with such Award. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Except as otherwise provided in this Third Amendment, the provisions of the Plan remain in full force and effect and are hereby ratified and confirmed.

<br>